EXAS
Price
$86.19
Change
+$16.51 (+23.69%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
16.33B
96 days until earnings call
Intraday BUY SELL Signals
RVTY
Price
$92.19
Change
-$0.87 (-0.93%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
10.46B
70 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EXAS vs RVTY

Header iconEXAS vs RVTY Comparison
Open Charts EXAS vs RVTYBanner chart's image
Exact Sciences
Price$86.19
Change+$16.51 (+23.69%)
Volume$239.35K
Capitalization16.33B
Revvity
Price$92.19
Change-$0.87 (-0.93%)
Volume$5.57K
Capitalization10.46B
EXAS vs RVTY Comparison Chart in %
EXAS
Daily Signal:
Gain/Loss:
RVTY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
EXAS vs. RVTY commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXAS is a Hold and RVTY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (EXAS: $86.18 vs. RVTY: $92.25)
Brand notoriety: EXAS: Notable vs. RVTY: Not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: EXAS: 688% vs. RVTY: 69%
Market capitalization -- EXAS: $16.33B vs. RVTY: $10.46B
EXAS [@Medical Specialties] is valued at $16.33B. RVTY’s [@Medical Specialties] market capitalization is $10.46B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $11.95B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXAS’s FA Score shows that 0 FA rating(s) are green whileRVTY’s FA Score has 0 green FA rating(s).

  • EXAS’s FA Score: 0 green, 5 red.
  • RVTY’s FA Score: 0 green, 5 red.
According to our system of comparison, RVTY is a better buy in the long-term than EXAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXAS’s TA Score shows that 3 TA indicator(s) are bullish while RVTY’s TA Score has 5 bullish TA indicator(s).

  • EXAS’s TA Score: 3 bullish, 5 bearish.
  • RVTY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RVTY is a better buy in the short-term than EXAS.

Price Growth

EXAS (@Medical Specialties) experienced а +26.05% price change this week, while RVTY (@Medical Specialties) price change was -2.00% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.75%. For the same industry, the average monthly price growth was -1.62%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

EXAS is expected to report earnings on Feb 24, 2026.

RVTY is expected to report earnings on Jan 29, 2026.

Industries' Descriptions

@Medical Specialties (-2.75% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXAS($16.3B) has a higher market cap than RVTY($10.5B). EXAS YTD gains are higher at: 53.372 vs. RVTY (-17.113). RVTY has higher annual earnings (EBITDA): 822M vs. EXAS (-758.48M). EXAS has less debt than RVTY: EXAS (2.52B) vs RVTY (3.38B). EXAS (2.94B) and RVTY (2.8B) have equivalent revenues.
EXASRVTYEXAS / RVTY
Capitalization16.3B10.5B155%
EBITDA-758.48M822M-92%
Gain YTD53.372-17.113-312%
P/E RatioN/A47.55-
Revenue2.94B2.8B105%
Total Cash858MN/A-
Total Debt2.52B3.38B75%
FUNDAMENTALS RATINGS
EXAS vs RVTY: Fundamental Ratings
EXAS
RVTY
OUTLOOK RATING
1..100
8469
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
44
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9584
PRICE GROWTH RATING
1..100
4059
P/E GROWTH RATING
1..100
10050
SEASONALITY SCORE
1..100
9085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXAS's Valuation (43) in the Biotechnology industry is in the same range as RVTY (44) in the Medical Specialties industry. This means that EXAS’s stock grew similarly to RVTY’s over the last 12 months.

EXAS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RVTY (100) in the Medical Specialties industry. This means that EXAS’s stock grew similarly to RVTY’s over the last 12 months.

RVTY's SMR Rating (84) in the Medical Specialties industry is in the same range as EXAS (95) in the Biotechnology industry. This means that RVTY’s stock grew similarly to EXAS’s over the last 12 months.

EXAS's Price Growth Rating (40) in the Biotechnology industry is in the same range as RVTY (59) in the Medical Specialties industry. This means that EXAS’s stock grew similarly to RVTY’s over the last 12 months.

RVTY's P/E Growth Rating (50) in the Medical Specialties industry is somewhat better than the same rating for EXAS (100) in the Biotechnology industry. This means that RVTY’s stock grew somewhat faster than EXAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXASRVTY
RSI
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
68%
Advances
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 9 days ago
67%
Declines
ODDS (%)
Bearish Trend 6 days ago
81%
Bearish Trend 3 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
57%
View a ticker or compare two or three
Interact to see
Advertisement
EXAS
Daily Signal:
Gain/Loss:
RVTY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
POWR25.370.04
+0.14%
iShares U.S. Power Infrastructure ETF
JPIB48.800.01
+0.02%
JPMorgan International Bond Opps ETF
JPI20.68N/A
N/A
Nuveen Preferred Securities & Income Opportunities Fund
HYKE24.98N/A
N/A
Vest 2 Year Interest Rate Hedge ETF
AVEE62.49-0.29
-0.45%
Avantis Emerging Markets Sm Cp Eq ETF

EXAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with QGEN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then QGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
+23.68%
QGEN - EXAS
55%
Loosely correlated
+0.18%
RGEN - EXAS
55%
Loosely correlated
+1.31%
A - EXAS
39%
Loosely correlated
+0.39%
RVTY - EXAS
39%
Loosely correlated
-0.87%
MTD - EXAS
38%
Loosely correlated
+0.57%
More

RVTY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RVTY has been closely correlated with MTD. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then MTD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RVTY
1D Price
Change %
RVTY100%
-0.87%
MTD - RVTY
81%
Closely correlated
+0.57%
A - RVTY
79%
Closely correlated
+0.39%
TMO - RVTY
77%
Closely correlated
-0.39%
WAT - RVTY
73%
Closely correlated
-0.10%
DHR - RVTY
71%
Closely correlated
-1.37%
More